Bayer has initiated the ALPINE-1 Phase II clinical trial to investigate BAY3283142, a soluble guanylate cyclase (sGC) activator, as a potential chronic kidney disease (CKD) treatment. CKD, a prevalent and potentially fatal condition affecting over 10% of the global population, is often unrecognized and can lead to cardiovascular complications.
This study aims to evaluate the efficacy and safety of BAY3283142 in patients with CKD. The sGC activator modulates the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) pathway, offering therapeutic potential for cardiovascular diseases.
The ALPINE-1 study is a randomized, double-blind, placebo-controlled trial designed to assess the treatment’s effects on CKD symptoms and progression. The positive results from this study could lead to the development of a much-needed therapeutic option for CKD patients and those at risk for related cardiovascular conditions.
Bayer’s commitment to advancing research and development in CKD and related diseases is evident in initiating the ALPINE-1 study. The company aims to improve patient outcomes and contribute to the well-being of those affected by these conditions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
